KK
BCRX icon

KLP Kapitalforvaltning’s BioCryst Pharmaceuticals BCRX Stock Holding History

KLP Kapitalforvaltning’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$459K Hold
45,900
– – ﹤0.01% 1540
2026
Q1 		$437K Buy
45,900
+3,000
+7% +$23.3K ﹤0.01% 1483
2025
Q4 		$335K Buy
42,900
+3,100
+8% +$22.4K ﹤0.01% 1607
2025
Q3 		$302K Hold
39,800
– – ﹤0.01% 1648
2025
Q2 		$357K Hold
39,800
– – ﹤0.01% 1514
2025
Q1 		$299K Hold
39,800
– – ﹤0.01% 1563
2024
Q4 		$299K Buy
+39,800
New +$302K ﹤0.01% 1652

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

KLP Kapitalforvaltning's BCRX Position: Q2 2026 in Review

KLP Kapitalforvaltning held its BioCryst Pharmaceuticals (BCRX) position steady in Q2 2026 at 45,900 shares worth $459K. The position accounts for ﹤0.01% of the portfolio, ranked #1540.

KLP Kapitalforvaltning first reported a position in BCRX in Q4 2024 and has held it in 7 quarters since. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • KLP Kapitalforvaltning held 45,900 shares of BioCryst Pharmaceuticals worth $459K as of Q2 2026.
  • KLP Kapitalforvaltning left its BioCryst Pharmaceuticals share count unchanged in Q2 2026.
  • BioCryst Pharmaceuticals made up ﹤0.01% of KLP Kapitalforvaltning's portfolio in Q2 2026, its #1540 holding.
  • KLP Kapitalforvaltning first reported a position in BioCryst Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on KLP Kapitalforvaltning's 13F filing for Q2 2026, filed 12 Aug 2026.